On tonight’s MAD MONEY on CNBC, Jim Cramer called for companies with high cash balances to make acquisitions while competitors are dirt cheap and vulnerable. Yesterday, Cramer called for Pfizer (NYSE: PFE)…
According to Reuters, JP Morgan (JPM), Bank of America (BAC), and Merrill Lynch (MER) will cut a total of almost 20,000 jobs. Reuters reports that Boeing (BA) will sign a new deal…
If you thought that high-premium buyouts or M&A was dead, that is not the case in at least some opportunities. Mentor Corp. (NYSE: MNT) has just secured a major premium buyout this…
Douglas A. McIntyre According to MarketWatch, shares in Rio Tinto (RTP) dropped 40% after BHP Billiton (BHP) dropped its offer for the company. According to Reuters, Citigroup’s (C) assurances that it did not need capital…
It looks as though not quite all the mergers are dead on the medical tech and biotechnology front. Johnson & Johnson (NYSE: JNJ) announced that it is acquiring Omrix Biopharmaceuticals, Inc. (NASDAQ:…
Douglas A. McIntyre We have outlined the changes we have seen in the holdings of Warren Buffett’s Berkshire Hathaway Inc. (NYSE: BRK-A) and these were put into groups in alphabetical order from I to S…
The Massachusetts Department of Public Health funded a study which is showing further evidence to support the use of drug eluting stents over bare metal stents in heart attack patients. This study…
These are some of the other non-tech analyst upgrades and downgrades from Wall Street firms this Wednesday morning: Constellation Energy (CEG) Raised to Buy at Jefferies. Denny’s (DENN) Raised to Buy at…
Johnson & Johnson (NYSE: JNJ) is showing that some companies can get it right despite tough times. The company has beat earnings and is even raising its fiscal 2008 guidance. The consumer…
Douglas A. McIntyre The market needed Johnson & Johnson (JNJ) to come though with big numbers to show that the consumer goods and medical devices markets, which to a large extent depend on consumer healthcare,…
Douglas A. McIntyre Analysts assume third quarter earnings for the companies in the S&P 500 will be bad. But, looking at the number which is the average of all firms in the index is misleading.…
A big up day in the market, say 4% or 5%, is not a rally, at least not any more. The DJIA has proved that it can move 1,000 points from bottom…
The list of management screw-ups at Boston Scientific (BSX) is almost too long to number. It bought rival Guidant and added $7 billion in debt in the process. Some of Guidant’s products…
According to Reuters, a Senate plan to vote on the bailout package pushed US markets up. Reuters reports that the FDIC would like to increase the value of the accounts it insures.…
You know it’s a rough day in the market when even defensive stocks are weak or mixed. We are at least seeing a mixed bag from some of these. But the trend…